Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000732592 | SCV000860566 | pathogenic | not provided | 2018-04-10 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000987917 | SCV001137410 | pathogenic | Progressive familial intrahepatic cholestasis type 1 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Genetics and Molecular Pathology, |
RCV003447558 | SCV004175670 | pathogenic | Low phospholipid associated cholelithiasis | 2021-11-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000732592 | SCV004294484 | pathogenic | not provided | 2024-06-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg159*) in the ABCB4 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ABCB4 are known to be pathogenic (PMID: 17726488, 25755532). This variant is present in population databases (rs377160065, gnomAD 0.005%). This premature translational stop signal has been observed in individual(s) with progressive familial intrahepatic cholestasis type 3 and low-phospholipid-associated cholelithiasis (PMID: 17726488, 23533021, 34961929). ClinVar contains an entry for this variant (Variation ID: 596680). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005046999 | SCV005674294 | pathogenic | Progressive familial intrahepatic cholestasis type 3; Low phospholipid associated cholelithiasis; Cholestasis, intrahepatic, of pregnancy, 3 | 2024-03-07 | criteria provided, single submitter | clinical testing | |
NIHR Bioresource Rare Diseases, |
RCV001003563 | SCV001161924 | likely pathogenic | Cholestasis, intrahepatic, of pregnancy, 3 | no assertion criteria provided | research | ||
Prevention |
RCV004535856 | SCV004710272 | pathogenic | ABCB4-related disorder | 2024-02-10 | no assertion criteria provided | clinical testing | The ABCB4 c.475C>T variant is predicted to result in premature protein termination (p.Arg159*). This variant was reported in the homozygous state to be causative for autosomal recessive progressive familial intrahepatic cholestasis (Table S4, Hertel et al. 2021. PubMed ID: 34016879; Bakır et al. 2021. PubMed ID: 34961929). This variant was also reported in the heterozygous state, in the absence of a second pathogenic variant, in association with autosomal recessive progressive familial intrahepatic cholestasis and low-phospholipid-associated cholelithiasis syndrome (Degiorgio et al. 2007. PubMed ID: 17726488; Poupon et al. 2013. PubMed ID: 23533021; Sharma et al. 2018. PubMed ID: 29973134). This variant is reported in 0.0050% of alleles in individuals of East Asian descent in gnomAD. Nonsense variants in ABCB4 are expected to be pathogenic. This variant is interpreted as pathogenic. |